Bil­lion­aire-backed Chi-Med de­clares PhI­II suc­cess for pi­o­neer­ing can­cer drug in Chi­na, seek­ing quick OK

Hutchi­son Chi­na MediTech has turned an im­por­tant cor­ner, scor­ing pos­i­tive over­all sur­vival and pro­gres­sion-free sur­vival in a Phase III study of fruquin­tinib, its lead on­col­o­gy drug, in colon can­cer. The top-line suc­cess — da­ta will come out this sum­mer at AS­CO — puts Chi-Med on a di­rect path with its part­ners at Eli Lil­ly to an NDA fil­ing with Chi­nese reg­u­la­tors in a few months.

In­ves­ti­ga­tors re­cruit­ed 416 pa­tients with lo­cal­ly ad­vanced or metasta­t­ic colon can­cer who had failed at least two chemother­a­pies for this study. The pa­tients were then divvied be­tween the drug arm and a group treat­ed with place­bo plus best stan­dard of care.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER